Pulmonx Posts 19-Cent Quarterly Loss as Micro-Cap Pressure Mounts
LUNG sits 75% above its 52-week low of $1.13.
Summary
Pulmonx reported a third-quarter loss of 19 cents a share, per Dow Jones, on revenue of $22.8M, up 6% year over year, as the company narrowed its loss. That follows a Q2 in which revenue slipped 5% to $22.8M on China headwinds while cost cuts narrowed the net loss by 34%. The company is burning cash at a micro-cap valuation, so the size of the quarterly loss matters more than usual for a name trading near $2. Watch whether the Q3 release shows the same cost discipline holding revenue steady, or whether the China drag deepened.
At the time of this announcement, LUNG was trading at $1.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85M. The 52-week trading range was $1.13 to $2.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.